News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BioLineRx Ltd. Receives Notice of Allowance From USPTO for Patent Covering BL-1020 Drug for Treatment of Schizophrenia


4/5/2011 10:49:21 AM

JERUSALEM, April 4, 2011 (GLOBE NEWSWIRE) -- BioLineRx (TASE:BLRX) announced today that a Notice of Allowance has been issued by the United States Patent and Trademark Office (USPTO) for a patent application covering the BL-1020 drug and its use for the treatment of schizophrenia. This patent, when formally issued, will be valid until September 2022 and may be eligible for a patent term extension of up to five years.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES